Prime Medicine, Inc. Increase (Decrease) in Equity Securities, FV-NI
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Equity Securities, FV-NI of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for the quarter ending 2026-06-30 was $0.00.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for the quarter ending 2026-03-31 was $0.00.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-12-31 was $539.00K, a 798.33% increase year-over-year.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for the quarter ending 2025-09-30 was $1.45M, a 576.28% increase year-over-year.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for fiscal 2025 was $432.00K.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for fiscal 2024 was -$484.00K.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for fiscal 2023 was -$2.38M.
- Prime Medicine, Inc. increase (decrease) in equity securities, fv-ni for fiscal 2022 was -$8.13M.
| Period end | Increase (Decrease) in Equity Securities, FV-NI 3 month | Increase (Decrease) in Equity Securities, FV-NI 6 month | Increase (Decrease) in Equity Securities, FV-NI 9 month | Increase (Decrease) in Equity Securities, FV-NI 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $539.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $539.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.99M derived: sum of 3 quarters · filed 2026-05-07 | $1.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.99M derived: sum of 2 quarters · filed 2026-03-03 | $1.49M derived: sum of 3 quarters · filed 2026-08-06 | $432.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $949.00K derived: sum of 2 quarters · filed 2026-08-06 | -$107.00K 10-Q · filed 2025-11-07 | -$47.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$505.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.56M 10-Q · filed 2026-08-06 | -$1.50M derived: sum of 3 quarters · filed 2026-08-06 | -$1.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.06M 10-Q · filed 2026-05-07 | -$996.00K derived: sum of 2 quarters · filed 2026-05-07 | -$781.00K derived: sum of 3 quarters · filed 2026-05-07 | -$2.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $275.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.65M derived: sum of 3 quarters · filed 2026-03-03 | -$484.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.71M derived: sum of 2 quarters · filed 2025-11-07 | -$544.00K 10-Q · filed 2025-11-07 | $91.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$759.00K 10-Q · filed 2025-08-07 | -$124.00K derived: sum of 3 quarters · filed 2025-08-07 | -$1.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-08 | $1.80M derived: sum of 2 quarters · filed 2025-05-08 | $222.00K derived: sum of 3 quarters · filed 2025-05-08 | $485.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$944.00K derived: sum of 2 quarters · filed 2025-02-28 | -$681.00K derived: sum of 3 quarters · filed 2025-02-28 | -$2.38M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.32M derived: sum of 2 quarters · filed 2024-11-12 | -$3.02M 10-Q · filed 2024-11-12 | -$4.73M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.44M 10-Q · filed 2024-08-08 | -$3.15M derived: sum of 3 quarters · filed 2024-08-08 | -$1.36M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.70M 10-Q · filed 2024-05-10 | -$3.41M derived: sum of 2 quarters · filed 2024-05-10 | -$1.62M derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $80.00K derived: sum of 2 quarters · filed 2024-03-01 | -$8.13M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$6.42M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$8.21M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |